Louisiana State Employees Retirement System Acquires New Position in Option Care Health, Inc. (NASDAQ:OPCH)

Louisiana State Employees Retirement System acquired a new stake in shares of Option Care Health, Inc. (NASDAQ:OPCH) during the fourth quarter, Holdings Channel.com reports. The fund acquired 49,700 shares of the company’s stock, valued at approximately $1,674,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in Option Care Health by 8.5% in the first quarter. BlackRock Inc. now owns 21,444,169 shares of the company’s stock worth $681,281,000 after acquiring an additional 1,671,783 shares in the last quarter. Vanguard Group Inc. grew its position in Option Care Health by 11.8% in the third quarter. Vanguard Group Inc. now owns 19,319,352 shares of the company’s stock worth $624,981,000 after acquiring an additional 2,037,162 shares in the last quarter. State Street Corp grew its position in Option Care Health by 1.0% in the second quarter. State Street Corp now owns 5,497,168 shares of the company’s stock worth $178,603,000 after acquiring an additional 52,404 shares in the last quarter. Third Point LLC grew its position in Option Care Health by 55.7% in the third quarter. Third Point LLC now owns 5,450,659 shares of the company’s stock worth $176,329,000 after acquiring an additional 1,950,659 shares in the last quarter. Finally, FMR LLC grew its position in Option Care Health by 10.8% in the third quarter. FMR LLC now owns 3,717,299 shares of the company’s stock worth $120,255,000 after acquiring an additional 362,828 shares in the last quarter. 98.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

OPCH has been the subject of a number of analyst reports. Jefferies Financial Group boosted their price objective on shares of Option Care Health from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, March 4th. Barrington Research boosted their price objective on shares of Option Care Health from $35.00 to $38.00 and gave the stock an “outperform” rating in a research note on Friday, February 23rd.

Insider Activity at Option Care Health

In related news, Director Harry M. Jansen Kraemer, Jr. bought 35,000 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was purchased at an average cost of $31.55 per share, for a total transaction of $1,104,250.00. Following the purchase, the director now directly owns 269,528 shares in the company, valued at $8,503,608.40. The purchase was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.64% of the company’s stock.

Option Care Health Price Performance

Shares of Option Care Health stock opened at $31.08 on Friday. The firm has a fifty day simple moving average of $32.27 and a 200-day simple moving average of $31.57. The company has a current ratio of 1.77, a quick ratio of 1.33 and a debt-to-equity ratio of 0.74. Option Care Health, Inc. has a 1-year low of $24.23 and a 1-year high of $35.74. The stock has a market capitalization of $5.40 billion, a price-to-earnings ratio of 21.14, a PEG ratio of 1.76 and a beta of 1.22.

Option Care Health (NASDAQ:OPCH) last released its earnings results on Thursday, February 22nd. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.29 by $0.03. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Option Care Health had a net margin of 6.21% and a return on equity of 18.78%. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.26 EPS. On average, sell-side analysts expect that Option Care Health, Inc. will post 1.13 earnings per share for the current year.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.